SAVA Q2 2023 Earnings — Cassava Sciences, Inc. Revenue & Financial Results | Market Cap Arena

SAVACassava Sciences, Inc.

$116M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$392,000

Operating Income

-$29M

Net Income

-$26M

EPS (Diluted)

$-0.63

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$20M

Stock-Based Comp.

$835,000

Balance Sheet

Total Assets

$197M

Total Liabilities

$18M

Stockholders' Equity

$179M

Cash & Equivalents

$168M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$392,000	-$17M	+97.7%
Operating Income	-$29M	-$20M	-44.5%
Net Income	-$26M	-$19M	-36.5%